Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR35579809

— · B

6cd654d1-8afb-5b2a-ad26-8b5e016e006b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V1+0.450
  • E2F_TARGETS+0.430
  • G2M_CHECKPOINT+0.400
  • MYC_TARGETS_V2+0.390
  • UNFOLDED_PROTEIN_RESPONSE+0.250
  • PANCREAS_BETA_CELLS+0.240
  • MITOTIC_SPINDLE+0.180
  • DNA_REPAIR+0.170
  • PROTEIN_SECRETION+0.170
  • SPERMATOGENESIS+0.120

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.410
  • INTERFERON_GAMMA_RESPONSE-0.410
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
  • ALLOGRAFT_REJECTION-0.350
  • INFLAMMATORY_RESPONSE-0.290
  • IL6_JAK_STAT3_SIGNALING-0.250
  • BILE_ACID_METABOLISM-0.230
  • XENOBIOTIC_METABOLISM-0.230
  • COMPLEMENT-0.210
  • NOTCH_SIGNALING-0.210

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MNG592
mng-umap@100
——0.887
2BS_1AYRM596
brain-umap@2
medulloblastoma—0.881
30edf46a2-3dfb-4bae-b642-281e05975bd1
melanoma-umap@29
——0.881
4BS_VT6C6N6K
brain-umap@2
medulloblastoma—0.865
5SRR15069603
head-neck@1
——0.860
6BS_81SP2HX4
brain-umap@2
medulloblastoma—0.855
7SRR33532819
breast-umap@18
—E0.855
8SJEPD030795_D3.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.849
9BS_BVSW4GTG
brain-umap@2
medulloblastoma—0.848
10AUR-AD9E-TTM1-A-1-1-R-A542-39
breast-umap@18
—B0.848

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V10.450Inavolisib— uncovered
E2F_TARGETS0.430Inavolisib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
MYC_TARGETS_V20.390Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.250Idelalisib— uncovered
PANCREAS_BETA_CELLS0.240Cobimetinib— uncovered
MITOTIC_SPINDLE0.180Inavolisib— uncovered
DNA_REPAIR0.170Idelalisib— uncovered
PROTEIN_SECRETION0.170Remibrutinib— uncovered
SPERMATOGENESIS0.120Inavolisib— uncovered
APICAL_JUNCTION0.090Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.090Inavolisib— uncovered
MTORC1_SIGNALING0.090Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.090Inavolisib— uncovered
TGF_BETA_SIGNALING0.080Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.060Remibrutinib— uncovered
UV_RESPONSE_UP0.030Idelalisib— uncovered
ANDROGEN_RESPONSE0.020Inavolisib— uncovered
COAGULATION0.020Binimetinib— uncovered
UV_RESPONSE_DN0.020Inavolisib— uncovered